Abstract
Evasion of apoptosis (programmed cell death) is a hallmark of pancreatic cancer, one of the leading causes of cancer deaths in the western world. Resistance to apoptosis can promote the multistep process of tumorigenesis, since tissue homeostasis is disturbed by too little cell death. Further, defects in apoptosis programs can leads to treatment failure in pancreatic cancer, since intact apoptosis pathways are critical to mediate therapy-induced cytotoxicity. Over the last decade, the exploration of apoptosis pathways and their dysregulation in pancreatic cancer has resulted in the identification of molecular targets that can be exploited for drug development and clinical application. Such apoptosis-based cancer therapeutics open new perspectives for rationally designed treatment strategies for patients with pancreatic cancer.
Keywords: Apoptosis, cancer, cancer therapy, resistance
Current Signal Transduction Therapy
Title: Exploiting Apoptosis Pathways for the Treatment of Pancreatic Cancer
Volume: 4 Issue: 1
Author(s): Simone Fulda
Affiliation:
Keywords: Apoptosis, cancer, cancer therapy, resistance
Abstract: Evasion of apoptosis (programmed cell death) is a hallmark of pancreatic cancer, one of the leading causes of cancer deaths in the western world. Resistance to apoptosis can promote the multistep process of tumorigenesis, since tissue homeostasis is disturbed by too little cell death. Further, defects in apoptosis programs can leads to treatment failure in pancreatic cancer, since intact apoptosis pathways are critical to mediate therapy-induced cytotoxicity. Over the last decade, the exploration of apoptosis pathways and their dysregulation in pancreatic cancer has resulted in the identification of molecular targets that can be exploited for drug development and clinical application. Such apoptosis-based cancer therapeutics open new perspectives for rationally designed treatment strategies for patients with pancreatic cancer.
Export Options
About this article
Cite this article as:
Fulda Simone, Exploiting Apoptosis Pathways for the Treatment of Pancreatic Cancer, Current Signal Transduction Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157436209787048676
DOI https://dx.doi.org/10.2174/157436209787048676 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Pool Maintenance During Oxidative Stress
Current Pharmaceutical Design Repositioning the Old Fungicide Ciclopirox for New Medical Uses
Current Pharmaceutical Design Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry GPR55, a Lysophosphatidylinositol Receptor with Cannabinoid Sensitivity?
Current Topics in Medicinal Chemistry Ex Vivo Proton NMR Analysis and Characterization of Thymus Lipid Metabolites and their Variation with Age in C57BL/6 Mice
Current Aging Science The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Research Progress on the Antitumor Effects of Rhein: Literature Review
Anti-Cancer Agents in Medicinal Chemistry Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Near Infrared Receptor-Targeted Nanoprobes for Early Diagnosis of Cancers
Current Medicinal Chemistry Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Expression Profiles and Bioinformatics Analysis of Full-length circRNA Isoforms in Gliomas
Current Bioinformatics Urokinase Receptor and Integrin Interactions
Current Pharmaceutical Design Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Advancements in Fuzzy C-means Based Techniques for Brain MRI Segmentation
Current Medical Imaging